Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

History and therapeutic rationale of long acting antipsychotics.

De Risio A, Lang AP.

Curr Clin Pharmacol. 2014 Feb;9(1):39-52. Review.

PMID:
23343446
2.

[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.

Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. French.

PMID:
23541914
3.

[French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].

Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca PM.

Encephale. 2013 Dec;39 Suppl 4:189-203. doi: 10.1016/S0013-7006(13)70121-0. French.

PMID:
24373464
4.
5.

[Antipsychotics].

Cattapan-Ludewig K, Seifritz E.

Ther Umsch. 2009 Jun;66(6):402-6. doi: 10.1024/0040-5930.66.6.402. German.

PMID:
19496035
6.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
7.

Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.

Agid O, Foussias G, Remington G.

Expert Opin Pharmacother. 2010 Oct;11(14):2301-17. doi: 10.1517/14656566.2010.499125. Review.

PMID:
20586707
8.

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V.

Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219. doi: 10.1177/2045125314540297. Review.

9.

[Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].

Schanda H, Stompe T.

Neuropsychiatr. 2010;24(1):14-26. Review. German.

PMID:
20146916
10.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients..

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

11.

[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].

Bret P, Bret MC, Queuille E.

Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7. French.

PMID:
19393381
12.

Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics.

Heres S, Lambert M, Vauth R.

Eur Psychiatry. 2014 Nov;29 Suppl 2:1409-13. doi: 10.1016/S0924-9338(14)70001-X. Epub 2014 Nov 22. Review.

13.

Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E.

Drugs. 2003;63(5):493-512. Review.

PMID:
12600227
14.

Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Masand PS, Gupta S.

Drugs Aging. 2003;20(15):1099-110. Review.

PMID:
14651433
15.

Treatment adherence in schizophrenia and schizoaffective disorder.

Goff DC, Hill M, Freudenreich O.

J Clin Psychiatry. 2011 Apr;72(4):e13. doi: 10.4088/JCP.9096tx6cc.

16.
17.

Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.

Park EJ, Amatya S, Kim MS, Park JH, Seol E, Lee H, Shin YH, Na DH.

Arch Pharm Res. 2013 Jun;36(6):651-9. doi: 10.1007/s12272-013-0105-7. Epub 2013 Apr 1. Review.

PMID:
23543652
18.

Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.

Morrissette DA, Stahl SM.

CNS Spectr. 2012 Nov;17 Suppl 1:10-21. doi: 10.1017/S1092852912000739. Review.

PMID:
23462201
19.

Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.

Barrio P, Batalla A, Castellví P, Hidalgo D, García M, Ortiz A, Grande I, Pons A, Parellada E.

Int Clin Psychopharmacol. 2013 Jul;28(4):164-70. doi: 10.1097/YIC.0b013e3283611cc3.

PMID:
23587986
20.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders..

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

Supplemental Content

Support Center